Article
Pharmacology & Pharmacy
Lin Fang, Weiping Tian, Chen Zhang, Xueyan Wang, Wanjing Li, Qi Zhang, Yuxin Zhang, Junnian Zheng
Summary: This study combined chimeric antigen receptor T-cell (CAR-T) therapy and oncolytic virus (OVs) as a potential treatment for solid tumors. The results showed that this combination therapy increased CAR-T cell infiltration and anti-tumor effects, demonstrating the potential and prospects of CAR-T in solid tumor treatment.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Chemistry, Multidisciplinary
Xinyuan Jia, Lizheng Wang, Xinyao Feng, Wenmo Liu, Xupu Wang, Fangshen Li, Xinyao Liu, Jiahao Yu, Bin Yu, Xianghui Yu
Summary: Cell membrane-coated oncolytic adenoviruses improve targeted infectivity on GBM cells and avoid preexisting immunity, providing a promising therapeutic strategy for glioma.
Article
Biochemistry & Molecular Biology
Che-Yuan Hu, Chi-Feng Hung, Pi-Che Chen, Jia-Yu Hsu, Chung-Teng Wang, Ming-Derg Lai, Yuh-Shyan Tsai, Ai-Li Shiau, Gia-Shing Shieh, Chao-Liang Wu
Summary: DCIR, an immunoreceptor, plays a role in inhibiting antitumor activity. The study demonstrates that using an oncolytic adenovirus can decrease the expression of DCIR in mice, inhibiting tumor growth and inducing stronger immune responses.
Article
Oncology
Sara Shayan, Arash Arashkia, Golnaz Bahramali, Asghar Abdoli, Mohammad Sadegh Shams Nosrati, Kayhan Azadmanesh
Summary: This study demonstrates that HSV-HMGB1 enhances the viability of colorectal cancer cells under hypoxic conditions by inducing autophagy. Understanding the characteristics of cancer cells, microenvironment, and cell signaling is crucial to improving therapeutic strategies.
CANCER CELL INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Lorella Tripodi, Maria Vitale, Vincenzo Cerullo, Lucio Pastore
Summary: Oncolytic adenoviruses (Onc.Ads) play an interesting role in immunotherapy due to their tumor selectivity, safety, and transgene-delivery capability. Their exceptional immunogenicity leads to a strong T-cell response, potentially making them more effective than current strategies. Various strategies can enhance Onc.Ads' antitumoral efficacy, including tumor microenvironment modulation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Zhong-Zhe Lin, Mickey C-T Hu, Chiun Hsu, Yao-Ming Wu, Yen-Shen Lu, Ja-An Annie Ho, Shiou-Hwei Yeh, Pei-Jer Chen, Ann-Lii Cheng
Summary: This study investigated the potential synergism of the telomerase-specific oncolytic adenovirus Telomelysin and the histone deacetylase inhibitor AR42 in treating hepatocellular carcinoma (HCC). Telomelysin and AR42 exhibited synergistic antiproliferative effects in in vitro and in vivo models of HCC. AR42 attenuated the expression of the coxsackievirus and adenovirus receptor and the mRNA levels of human telomerase reverse transcriptase, enhancing the cytotoxicity of Telomelysin.
Article
Pharmacology & Pharmacy
Mariangela Garofalo, Federica Bellato, Salvatore Magliocca, Alessio Malfanti, Lukasz Kuryk, Beate Rinner, Samuele Negro, Stefano Salmaso, Paolo Caliceti, Francesca Mastrotto
Summary: This study explored the use of polymer-coated oncolytic viruses for the treatment of hepatocellular carcinoma, showing higher therapeutic efficacy in cells expressing high levels of ASGPR. The polymer coating altered the viral properties, enhancing infectivity and immunogenic cell death compared to naked viruses.
Article
Multidisciplinary Sciences
Akash K. Kaushik, Amy Tarangelo, Lindsey K. Boroughs, Mukundan Ragavan, Yuanyuan Zhang, Cheng-Yang Wu, Xiangyi Li, Kristen Ahumada, Jui-Chung Chiang, Vanina T. Tcheuyap, Faeze Saatchi, Quyen N. Do, Cissy Yong, Tracy Rosales, Christina Stevens, Aparna D. Rao, Brandon Faubert, Panayotis Pachnis, Lauren G. Zacharias, Hieu Vu, Feng Cai, Thomas P. Mathews, Giannicola Genovese, Barbara S. Slusher, Payal Kapur, Xiankai Sun, Matthew Merritt, James Brugarolas, Ralph J. DeBerardinis
Summary: This study analyzed the metabolism of patient-derived xenografts from different subtypes of renal cell carcinoma. The findings showed that tumorgrafts from VHL-mutant clear cell RCC catabolize glutamine through multiple pathways, which may explain the challenges in achieving therapeutic responses by inhibiting glutaminase.
Article
Biotechnology & Applied Microbiology
Mary K. McKenna, Alexander Englisch, Benjamin Brenner, Tyler Smith, Valentina Hoyos, Masataka Suzuki, Malcolm K. Brenner
Summary: Using mesenchymal stromal cells (MSCs) to systemically deliver a binary vector containing OAd and HDAd improves tumor therapy effectiveness. CAd-infected MSCs deliver functional virus, stimulating CAR-T cell anti-tumor activity through IL-12 and PD-L1 blocker release.
Article
Engineering, Biomedical
Jia Yang, Rui Zheng, Muhetaerjiang Mamuti, Da-Yong Hou, Yong-Dan Zhao, Hong-Wei An, Hao Wang, Yuliang Zhao
Summary: A tumor-activated oncolytic peptide nanomachine has been developed for treating multidrug-resistant tumors by selectively lysing tumor cell membranes.
Editorial Material
Oncology
Elizabeth P. Henske, Liang Cheng, A. Ari Hakimi, Toni K. Choueiri, David A. Braun
Summary: Chromophobe renal cell carcinoma (ChRCC) is the second most common variant of non-clear cell renal cell carcinoma. ChRCC differs from clear cell RCC (ccRCC) in terms of genetics, genomics, metabolism, cell of origin, and response to targeted and immune therapies. The pathogenesis of ChRCC is not well understood, but current evidence suggests two potential mechanisms: mTORC1 hyperactivation through PTEN pathway mutations and mitochondrial dysfunction leading to oxidative stress.
Article
Biochemistry & Molecular Biology
Junhui Hu, Desmond J. Smith, Lily Wu
Summary: This study characterized the biochemical activity, transcriptomic hypoxia signature, and biological functions of the L169P variant in the von Hippel-Lindau (VHL) tumor suppressor gene. The results showed that the L169P variant has comparable protein stability, ability to degrade HIF1 alpha and HIF2 alpha, and ability to regulate hypoxia gene expression as the wildtype VHL. Additionally, the L169P variant exhibited similar suppression of ccRCC tumor cell growth compared to the wildtype VHL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Agata Swiatkowska
Summary: p53 is a crucial transcription factor for maintaining cellular homeostasis, and its mutations are strongly linked to tumor development. Different isoforms of p53 have been identified, which can modulate its activity under stress conditions. In renal cancer, mutations in the VHL gene are associated with the most common subtype, renal cell carcinoma (RCC), and the VHL protein is essential for full activation of p53. Changes in the expression of p53 isoforms are associated with different stages of RCC and overall survival.
Article
Chemistry, Multidisciplinary
Zhaoqing Cong, Songsong Tang, Leiming Xie, Ming Yang, Yangyang Li, Dongdong Lu, Jiahong Li, Qingxin Yang, Qiwei Chen, Zhiqiang Zhang, Xueji Zhang, Song Wu
Summary: A unique robotic medical platform is designed using cell robots as carriers to selectively bind and kill tumors with oncolytic adenovirus. The cell robots are modified and coated to enable specific targeting and movement within the body, resulting in enhanced efficacy in tumor treatment.
ADVANCED MATERIALS
(2022)
Article
Biochemistry & Molecular Biology
Anna Gluba-Brzozka, Jacek Rysz, Janusz Lawinski, Beata Franczyk
Summary: Cancers are a leading cause of disability and death, and obesity may promote the development of renal cell carcinoma through factors such as dysregulated cell metabolism, excessive nutrients, and altered gene expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
